Deficiency of PTEN Confers Hypersensitivity to Fatty Acid-Mediated ER Stress in Transformed Hepatocytes
International Journal of Molecular Sciences · 19.03.2026 · 27 (6) · 2778
DOI: 10.3390/ijms27062778 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 19.03.2026. Verfasst von Olaya Yassin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Drug Research, The Hebrew University of Jerusalem, Jerusalem 9112001, Israel. Hauptthemen laut MEDLINE: PTEN Phosphohydrolase, Endoplasmic Reticulum Stress, Hepatocytes, Liver Neoplasms. Die Arbeit nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Israel Science Foundation, Israel Innovation Authority, Israeli Science Foundation.
Abstract (Originalsprache)
Deletion of the tumor suppressor gene phosphatase and tensin homolog (PTEN) in hepatocellular carcinoma (HCC) is associated with a poor response to therapy and reduced survival. In mice, the deletion of PTEN in hepatocytes generates steatosis; however, on the background of steatosis not all emerging HCC cells lack PTEN, suggesting that steatosis confers a metabolic liability to proliferating PTEN-deficient hepatocytes. Here, we show that PTEN-deficient HepG2 cells develop terminal stress in the endoplasmic reticulum (ER) and profound apoptosis when exposed to a mixture of oleic and palmitic acids, while control cells do not. Lipidomic analyses before and after the treatment indicate a higher increase in triglycerides in PTEN KO cells, as well as profound differences in phospholipid concentrations. Although the triglyceride content increases, the coalescence into lipid droplets was impaired in the KO cells, together with a reduction in β-oxidation. Xenograft studies showed that PTEN KO HCC tumors progressed faster than did the control tumors when mice were fed with normal chow and slower under a high-fat diet. We suggest that while the health risks of a fatty acid-rich diet to liver function and the increased propensity to develop HCC are prominent, once a PTEN-deficient HCC has been established, it exposes vulnerability to lipid overload that can be exploited through diet and pharmacological interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Drug Research, The Hebrew University of Jerusalem, Jerusalem 9112001, Israel.
- Department of Biochemistry, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
- Department of Pharmacology, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
- Department of Applied Sciences, Northumbria University, Newcastle upon Tyne NE1 8ST, UK.
ORCID-Profile: Olaya Yassin, Ata Abbas, William C Merrick, Antony Antoniou, Shakti P Pattanayak, Boaz Tirosh
Förderung
- Israel Science Foundation
- Israel Innovation Authority
- Israeli Science Foundation
- NCI
Zitieren
APA
Yassin, O., Darawshi, O., Wang, F., Zhang, Y., Abbas, A., Merrick, W. C., Cheung, W., Antoniou, A., Pattanayak, S. P., & Tirosh, B. (2026). Deficiency of PTEN Confers Hypersensitivity to Fatty Acid-Mediated ER Stress in Transformed Hepatocytes. International Journal of Molecular Sciences, 27(6), 2778. https://doi.org/10.3390/ijms27062778
Vancouver
Yassin O, Darawshi O, Wang F, Zhang Y, Abbas A, Merrick WC, et al. Deficiency of PTEN Confers Hypersensitivity to Fatty Acid-Mediated ER Stress in Transformed Hepatocytes. International Journal of Molecular Sciences. 2026;27(6):2778. doi:10.3390/ijms27062778
BibTeX
@article{Yassin2026,
author = {Yassin, Olaya and Darawshi, Odai and Wang, Fangfang and Zhang, Youwei and Abbas, Ata and Merrick, William C and Cheung, William and Antoniou, Antony and Pattanayak, Shakti P and Tirosh, Boaz},
title = {Deficiency of PTEN Confers Hypersensitivity to Fatty Acid-Mediated ER Stress in Transformed Hepatocytes},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {6},
pages = {2778},
doi = {10.3390/ijms27062778}
}
EUVIMED